XRTX under $4

Yesterday, XRTX.v highlighted its important 2023 milestones, like receiving special designation from the FDA for its kidney disease treatment & getting closer to receiving accelerated approval. XRTX plans to keep up this momentum in 2024, conducting advanced clinical trials & working through regulatory processes.
https://www.xortx.com/news/press-releases/detail/151/xortx-highlights-achievements-of-2023-and-preparation-for

With the submission of a new patent for the treatment of chronic kidney disease, XRTX has made a positive step in its pipeline, in addition to its its Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD:

New on my Radar - @XORTXinc $XRTX $XRTX.v

➡️Late-stage clinical pharmaceutical & drug-based #biotechnology company focused on orphan disease indications

➡️Developing innovative therapies to improve the quality of life of patients with progressive kidney disease & diabetes… pic.twitter.com/ixpkt2Hm8o

— Stock Master Flash (@StckMasterFlash) March 8, 2024

XRTX is advancing treatments for polycystic kidney disease & diabetic nephropathy, w/ promising clinical trials, a significant market opportunity considering the growing prevalence of these diseases worldwide.

New on my Radar - XORTX Therapeutics (NASDAQ/TSXV: XRTX) - $14/share Price Target from Alliance Global Partners: https://www.reddit.com/r/biotech_stocks/comments/1ba1j8w/new_on_my_radar_xortx_therapeutics_nasdaqtsxv/

XRTX report from LinkedIn:

We are pleased to bring investors the new, special report by The Venture Letter™ venture stock newsletter on XORTX Therapeutics Inc. (NASDAQ & TSXV: XRTX), officially released last week. https://theventureletter.com/wp-content/uploads/2024/02/TVL-Special-Report-XORTX-Therapeutics-Inc.-0224.pdf[/tag]

We are excited by the prospects for XORTX and the company’s efforts to provide new and much-needed orphan drug therapy to slow progressive kidney disease.

We invite everyone to read our special report and take a close look at XORTX Therapeutics, now approaching its third and most important FDA drug trial. Biotech stocks are in a bull market right now and we see XRTX as a perfect company to investigate.

Good luck and good hunting.

#theventureletter #stocksinfocus #XORTX #XRTX #biotech #biotechs #biotechstocks #XBI #nasdaqlisted #stocks

$XRTX XORTX Announces $2 Million Public Offering

https://www.globenewswire.com/news-release/2024/01/15/2809090/0/en/XORTX-Announces-2-Million-Public-Offering.html

CALGARY, Alberta, Jan. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the filing of a prospectus supplement on a non-brokered offering of up to 666,667 common share units (“Common Share Units”), with each Common Share Unit consisting of one common share, no par value, and one warrant (“Warrant”) to purchase one common share at $4.50 per common share for a period of two years for aggregate gross proceeds of up to $2 million, prior to deducting offering expenses (the “Offering”). The common shares and Warrants contained in the Common Share Units are immediately separable upon issuance. The Warrants have an initial exercise price of $4.50 per share, will be immediately exercisable, and may be exercised for two years from the date of issuance, provided, however that, if, the common shares on the TSX Venture Exchange (“TSXV”) trade at greater than $6.00 for 10 or more consecutive trading days, the Warrants will be accelerated and the Warrants will expire on the 30th business day following the date of such notice.

The Offering is expected to close on or about January 25, 2024, subject to satisfaction of customary closing conditions.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The Company also announces that it has entered into a consulting agreement with Plutus Bridge Capital Inc. (“Plutus”) to provide social media marketing and related services in accordance with TSXV policies (the “Consulting Agreement”). Plutus is an independently owned public relations and capital markets consultancy firm based in Vancouver, British Columbia. In connection with the engagement, the Company has advanced US$25,000 plus applicable taxes to cover the start-up costs associated with the public relations campaign and related services. A further budget will be required to expand the program at the discretion and approval of the Company. The engagement is for an initial term of six months until June 30, 2024. The Consulting Agreement can be extended by mutual consent and can be terminated by either party on 30 days written notice. XORTX and Plutus are unrelated and unaffiliated entities. Plutus has informed the Company that it currently has no present, direct or indirect, interest in XORTX or any securities of XORTX.

$XRTX An eventful 2024 on tap for Xorlo development

https://europac.bluematrix.com/sellside/EmailDocViewer?encrypt=55bd6855-bb6e-49cb-bac2-a7757d387797&mime=pdf&co=europac&id=nick@alpineequityadv.com&source=mail

$XRTX XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease

https://www.globenewswire.com/news-release/2024/01/03/2803143/0/en/XORTX-Submits-a-New-Patent-for-the-Treatment-of-Chronic-Kidney-Disease.html

CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”). This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD. Importantly, this patent entitled “Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease” outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (XOI) in the setting of CKD in particular autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.

The positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported in Q1 2023 (the “Study”) characterized the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLO™. Results from the Study showed that XORLO™ was well tolerated by the 88 subjects who received the drug. There were no safety concerns during the testing of drug across the various dosing regimens used. Overall results were positive and showed: i) a substantial increase in the bioavailability of oxypurinol with the XORLO™ formulation platform; (ii) a substantially increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values. In simple terms, substantially increased early oral absorption of XORLO™, and increased circulating concentrations of oxypurinol necessary to inhibit production of uric acid across the desired therapeutic range and thereby slow down the advancements of CKD. Each of these results will provide key data to facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease due to ADPKD as well as other causes of CKD.

Dr. Allen Davidoff, CEO of XORTX, commented, “The Bridging Pharmacokinetic Study reported this year provided a wealth of clinical data regarding the potential substantive benefit of the novel formulations of the xanthine inhibitor class of drugs. Analysis of this data set, the use of in silico based pharmacokinetic modeling of data from the XRX-OXY-101 clinical trial, and further innovation, resulted in a deeper understanding of how to address the challenges of dosing in progressing kidney disease. This patent application is intended to claim new opportunities to enhance how the xanthine oxidase inhibitor class of drugs may be dosed in the future. Importantly, how to further improve the safe and effective administration of this class of drugs, including oxypurinol.”

$XRTX: XORTX Clarifies Timing for Share Consolidation
Nov. 10, 2023 7:00 AM ETXORTX Therapeutics Inc. (XRTX), XRTX:CA

CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XRTX) ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of November 8th, the consolidation of the Company’s common shares on the basis of one post-consolidation Share for every nine pre-consolidation Shares (the “Consolidation”), will now be undertaken today with the shares expected to begin trading on a post-consolidation basis on the TSX Venture Exchange (“TSXV”) and the Nasdaq Capital Market (“Nasdaq”) when markets open on or about Tuesday, November 14, 2023.

The Shares will continue to trade on the TSXV and Nasdaq under the symbol “XRTX” on a post-Consolidation basis, under a new CUSIP number – 98420Q306.

The Consolidation has been approved by the TSX Venture Exchange (the “TSXV”) and follows approval of a consolidation of the Shares on the basis of a range of up to nine pre-consolidation Shares for every one post-consolidation Share at the special meeting of shareholders of the Company held on October 27, 2023. As a result of the Consolidation, the number of issued and outstanding Shares will be reduced from 17,989,687 to approximately 1,998,854, subject to adjustment for rounding. No fractional shares will be issued in connection with the Consolidation. If a holder of Shares would otherwise be entitled to a fraction of a share, then the number of post-Consolidation Shares issuable to such shareholder shall be rounded down to the next lower whole number. No cash consideration will be paid in respect of fractional shares. The exercise or conversion price and/or the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.

Shareholders of record as of the Effective Date will receive a letter of transmittal from TSX Trust Company, the transfer agent for the Shares, providing instructions for the exchange of their Shares as soon as practicable following the Effective Date. Until surrendered, each share certificate representing pre-Consolidation Shares will represent the number of whole post-Consolidation shares to which the holder is entitled as a result of the Consolidation.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Respiratory Viral infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients with kidney disease. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:

Allen Davidoff, CEO
adavidoff@xortx.com or +1 403 455 7727
Nick Rigopulos, Director of Communications
nick@alpineequityadv.com or +1 617 901 0785

Media Inquiries, OIipriya Das, PhD, MSc
olipriya.das@russopartnersllc.com or +1 409 365 3641


Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

https://www.globenewswire.com/newsroom/ti?nf=ODk3NzA4NiM1OTIyMzE3IzIwOTcyNzk=

#DDAmanda Chart on: $XRTX :
+
You can find these before they run.

#DDAmanda Halloween Special: https://ddamanda.com/SignUpHalloween164.php



#DDAmanda is still the best way to find #WinningStocks before they run.
Contact/Text: 760 702-2009

Trial Subscription: https://www.ddamanda.com/SignUpDaily.php

What the Fact (Factor) Column is:

The Factor is a proprietary indicator used for scanning in #DDAmanda.

It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).

SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.

That's significant, and many times indicates that a run in the stock is coming.

XRTX: And it finally DID soar!!!

.96 was yesterday ah high fun to watch

XRTX: Indeed!! (I thought it might SOAR from these levels today.)

I am wondering how some people feel today, when they got in from .80 to .96 last night?
This prices may help R/S to qualify for Nasdaq listing again which will be discussed in shareholder meeting next week, IMO.

XRTX: Admiral C-O-24!!! Yep!! What a craps-shoot today!! A bunch looked like they might soar --- and XRTX too, of course --- but I suspect that only XRTX will survive this day as the WINNER!! (Could be as simple as Peeps are suddenly FASCINATED by the 'Mystery' plays --- where EVERYBODY & EVERYTHING is absolutely CLUELESS as to why it is moving UP.)

Shares of XRTX are trending on Yahoo Finance and moving on remarkably heavy trading volume Friday, despite a lack of company-specific news.

According to data from Benzinga Pro, more than 45 million shares have already been traded in the session, compared to the stock's 100-day average of just over 200 thousand shares.

Xortx Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.

Related News: What's Going On With Bitcoin Mining Stocks Marathon Digital And Riot Platforms?

XRTX Price Action: According to Benzinga Pro, Xortx Therapeutics shares are up 52% at 53 cents at the time of publication.

XRTX: And to Jupiter from here!! (And for NO frickin' rational reasons whatsoever.)

Out...See if the gap will fill... See if the big buyer will be back today... see what this open offering is about

Buying the dip here

I don’t think it is up 220% due to R/S, lol.

I have seen some wild swings with XRTX in the past years, but not like today.

One of the few other thing can happen here?

a) Partnership to manufacture one of their drug.
b) Buy out?
c) Approval by FDA
d) Short covering?
e) Others?

Either way, I am expecting delayed opening in the morning by TSX.

XRTX: And the SMART traders have ALREADY dumped their (at least) $10K bucks toss at this in the POST-Mkt.!!!!

Wild isn't it? Chit running for no reason I can find. Lol!

Who’s poking it?

XRTX new 52 week low

R/S or delisting vote

Whats cooking here

Today(as of now), premarket trading is normal which is less than 500,000 shares have traded so far.
I am sure exchange took care of yesterday’s problem which was not good for the company and retail shareholders.

Most of volume came from pre market trading early this morning and I was watching it. It was trading 1.40$+ ( the highest) and look at the closing .87c, lol.

shorts are feeling the pain onGNS but that doesnt help XRTX

Don't surprise me any this market is getting away with murder. Mmtlp cracked me up . Opps these guys are going to make.t9 much money we better halt trading two days early . What a joke avct filling chapter 11 after pumping a merger with Amazon.

I could go on and on but I'm sure you are well aware . It's to the point I am thinking about bagging the market

Very

based off the float, news and volume, this is criminal imo

Yes sir load up

Time to buy more$$$$

This should be Higher $$$$$

.87 reload looks good

$XRTX XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

https://finance.yahoo.com/news/xortx-announces-positive-topline-results-120000475.html

news
XORTX Therapeutics prices $5M underwritten public offering
https://seekingalpha.com/news/3888565-xortx-therapeutics-prices-5m-underwritten-public-offering?utm_source=otcmarkets&utm_medium=referral

XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial
Clinical Trial Shows Substantially Improved Bioavailiability
CALGARY, Alberta, July 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce positive topline results from Part 1 of the three part Pharmacokinetics Bridging Study – XRX-OXY-101 (“PK Clinical Trial”) - showing a substantial increase in oral bioavailability of two versions of XORTX’s proprietary oxypurinol formulation compared to a control formulation. In addition, accompanying the improved bioavailability findings in Part 1 of the PK Clinical Trial was a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol.

Successful recruitment, administration of a single oral dose of drug formulation, blood sampling and bioanalytical evaluation were conducted in Part 1 of the PK Clinical Trial to characterize the pharmacokinetics and bioavailability of the unique proprietary formulations in advance of the Company’s planned late-stage phase 3 registration trial in autosomal dominant polycystic kidney disease (“ADPKD”).

The PK Clinical Trial is undertaken in three parts and designed with four important objectives: 1) to determine which of XORTX’s novel formulations results in the greatest circulating oxypurinol concentrations and oxypurinol exposure; 2) to determine the effect of food on the bioavailability of the selected formulation; 3) to determine the effect of dose on the bioavailability of the selected formulation; and 4) to determine the safety and pharmacokinetics of multiple doses of the selected formulation. Knowledge gained during the conduct of this PK Clinical Trial will provide guidance regarding the formulation selected and the oral dosing regimen necessary to reach and maintain the target circulating concentration of oxypurinol. Part 1 of the PK Clinical Trial involved dosing under fasted conditions. Part 2 will measure the effect of food on pharmacokinetics and Part 3 is a multiple dose pharmacokinetics evaluation. The PK Clinicial Trial is designed to permit XORTX to characterize the safety and relative bioavailability of the XRx-008 program formulations. Knowledge gained during the conduct of this PK Clinical Trial is now providing critical guidance regarding the oral dosing for our planned phase 3 registration trial in ADPKD.

Part 1 of the XRX-OXY-101 achieved the following purposes:

Confirmed improved human bioavailability of XORTX formulations of oxypurinol for future development;
Established a pharmacokinetics data set characterizing oral bioavailability of XORTX formulations for future population based pharmacokinetic modeling;
Confirmed the unique proprietary formulation innovations from recently granted US and EU patents that provide for increased circulating concentrations of oxypurinol; and
Built upon the pharmacokinetic and safety database of safety and efficacy for oxypurinol.
Dr. Allen Davidoff, CEO of XORTX, stated, “Successful completion of Part 1 of the XRX-OXY-101 Study provides important knowledge for selecting the clinical dose and formulation for future oral dosing in our upcoming phase 3 registration trial. Pharmacokinetic modeling of this data will provide additional information to guide decision making as we plan and execute development of the XRx-008 program clinical and commercial development. We look forward to the initiation of dosing of Part 2 of the XRX-OXY-101 this week.”

About ADPKD

ADPKD is a rare disease that affects more that 10 million individuals worldwide.1,2 ADPKD is typically diagnosed based upon expansion of fluid-filled cysts in the kidneys. Over time, the increasing number and size of cysts can contribute to structural and functional changes to kidneys and is frequently accompanied by chronic pain which is a common problem for patients with ADPKD.3 Expansion of cysts is thought to compress healthy functioning tissue surrounding the cysts and contribute to further loss of kidney function, fibrosis, impaired nutrient exchange and impaired kidney function, accompanied later by end-stage renal disease.1 For individuals with progressing ADPKD, treatment recommendations include anti-hypertensive treatment, dietary restrictions, and, for a limited percentage of suitable patients, pharmacotherapy.4 New, more broadly applicable therapies to effectively slow decline of kidney function in ADPKD are needed.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.

For further information, please contact:

Allen Davidoff, CEO
adavidoff@xortx.com or +1 403 455 7727

Really well, have you seen analyst price targets…$26pps!!!

I know right? It’s holding up well…

Is no one watching what is happening here!! Sheesh

NEW $XRTX $XRX CEO interview: Pioneering Kidney Disease Therapies for COVID Patients

Thanks!! Ticker change submitted to Admin.

$XRTX: $XRTX will be the new SYMBOL !!!!!!


Now at $3.17



https://www.xortx.com/2021/10/13/xortx-therapeutics-announces-pricing-of-us12-million-public-offering-and-nasdaq-listing/




GO $XRTX





**************************************************************



XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing
CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces the pricing of an underwritten public offering of 2,906,000 units (“Units”), with each Unit consisting of one common share, no par value, and one warrant (“Warrant”) to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses and excluding any exercise of the underwriters’ option to purchase any additional securities as described herein (the “Offering”). The common shares and warrants contained in the Units are immediately separable upon issuance. The warrants have an initial exercise price of US$4.77 per share, will be immediately exercisable, and will have a term of approximately five years. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 435,900 common shares and/or warrants to purchase up to an additional 435,900 common shares at the Offering price less the underwriting discounts. The Company has received conditional approval to list its common shares on the Nasdaq Capital Market (“Nasdaq”) under the symbol “XRTX” and is expected to begin trading today. The Offering is expected to close on or about October 15, 2021, subject to satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole book-running manager for the Offering.

The U.S. Securities and Exchange Commission (the “SEC”) declared effective a registration statement on Form F-1 relating to these securities on October 12, 2021. A final prospectus relating to the Offering will be filed with the SEC. The Offering is being made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained, when available, by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by email at prospectus@allianceg.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at https://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.

For further information, please contact:
Allen Davidoff, CEO Nick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727 nick@alpineequityadv.com or +1 617 901 0785
Dr. David Sans, Head of Corporate Development in New York City
dsans123@xortx.com or +1 347 573 0541

XRTXF moved to the Nasdaq from the OTC. *** I searched 100+ pages of SEC filings and there is no mention what the new ticker will be.



https://otce.finra.org/otce/dailyList?viewType=Deletions

XRTXF one for 11.74 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Wanted them at .26 this morning but did not want to take a loss on another one that I would have to sell to get them. Ended up taking that loss to get this one at .35

Smart money buying this up. Canadian volume just ramping up